Indication intelligence, analysis and sector perception

WHO, WHAT, WHEN, WHERE and WHY

March 10, 2021 5:37pm

Biostage (BSTG) closed down again -$0.00 to $1.50 with 1,505 - "pumped" after Tuesday's -$0.10 to $1.50 with 1,254 shares traded, Monday’s -$0.03 to $1.60 with 6,196 shares traded (pumped re promoted”), being flat Friday with 217 shares traded, Thursday’s 2,083 shares being traded and last Wednesday’s being flat at $1.63 with 32 shares traded. Reiterating some serious questions that have yet and need to be answered ...

Question#1: About WHO, are the reasons of WHY have all these posts of questions been asked by PUBLIC shareholders and NEVER been answered emanated from – Who terminated WITHOUT CAUSE the TURNAROUND team that focused the IND, questioned the “shadow” operations of the company, probed the financial structures of GIFT and research support expenditures, queried the shareholdings of research providers and investigators, enquired about the lease status (which could have been dramatically reduced) and ultimately investigated the cost structure of operations in addition to the financing and the “ODD” control of company of WHO was really calling the “shots” at BSTG?

Question#2: WHY and for WHAT reasons did this individual hope to perpetrate these conditions UPON U.S. public shareholders especially in relation to “misplacing or losing” many accounts payable and accrued and other current “liabilities”?

Question#3: Also, WHO and WHERE is the financial officer or principal accounting officer of the company – still NOT recruited as the Q4 and FY20: 8-K and 10-Q are due? JUST WHAT is RSM US LLP auditing?

Question#4: Don’t these questions of issues put MORE governmental, fiduciary and transparency responsibility on the new board and audit committee member, Herman Sanchez and RSM US LLP as to the potentials or the possibilities of SEC investigation(s)?

MINORITY PUBLIC shareholders are waiting, watching and weighting responses to MAINTAIN their RIGHTS.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.